Loading…
MapLight Therapeutics, Inc. is projected to rise to $50.09 by 2027, a +27% move from its current price of $39.32. MPLT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $37.91 | $39.33 | $40.82 | +0.03% |
| Jul 14 | $37.34 | $39.35 | $41.46 | +0.07% |
| Jul 15 | $36.92 | $39.36 | $41.96 | +0.10% |
| Jul 16 | $36.57 | $39.37 | $42.40 | +0.14% |
| Jul 17 | $36.26 | $39.39 | $42.78 | +0.17% |
| Jul 18 | $35.99 | $39.40 | $43.14 | +0.21% |
| Jul 19 | $35.74 | $39.42 | $43.47 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $35.74 | $39.42 | $43.47 | +0.24% |
| Week 2 | $34.40 | $39.51 | $45.37 | +0.48% |
| Week 3 | $33.43 | $39.61 | $46.92 | +0.73% |
| Week 4 | $32.64 | $39.70 | $48.28 | +0.97% |
| Week 5 | $31.98 | $39.80 | $49.53 | +1.22% |
| Week 6 | $31.39 | $39.89 | $50.70 | +1.46% |
| Week 7 | $30.87 | $39.99 | $51.81 | +1.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease.
ML-055 is aimed at neuropsychiatric conditions, and ML-009 is a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops a platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc.
and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
MapLight Therapeutics, Inc. (MPLT) is currently priced at $39.80 per share with a market capitalization around $1.8B and a rank of 2134. These figures place MPLT among healthcare peers with a substantial market footprint in its sector.
The near-term outlook is reflected in the 2026 forecast, which shows an average price of $39.80, a low of $15.70 and a high of $58.08, with a neutral sentiment.
A major floor 56.8% below — a decisive break under it would weaken the trend.
The nearest floor, 30.9% below — buyers have tended to step in here.
Price is pressing into resistance (1.2% away) — a breakout level to watch.
A major ceiling 22.2% above — clearing it would confirm fresh momentum.
Key MPLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MPLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.95 | Buy | $38.27 | Buy |
| MA 10 | $36.63 | Buy | $36.58 | Buy |
| MA 20 | $32.93 | Buy | $34.25 | Buy |
| MA 50 | $30.61 | Buy | $30.86 | Buy |
| MA 100 | $26.09 | Buy | $27.47 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.94 | Neutral |
| Stoch RSI (14) | 90.63 | Sell |
| CCI (20) | 115.03 | Buy |
| Williams %R (14) | -4.30 | Info |
| MACD (12,26,9) | 0.72 | Buy |
| ROC (12) | 37.29 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 95.70 | Sell |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 6.63 | Buy |
| Ultimate (7,14,28) | 71.96 | Sell |
| Momentum (10) | 7.36 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 39.71 | Sell |
| ADX (14) | 22.28 | Buy |
| ATR (14) | 1.24 | Info |
Technical sentiment remains BULLISH, with RSI14 at 70 and a 50-day simple moving average of $30.43. The near-term picture is anchored by a 30-day range of $30.98 to $51.13, indicating potential for upside toward the suggested resistance level of $39.80 while maintaining a support level at $27.16.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.70 | $39.32 | $57.23 | 0% | Neutral | |
| $36.06 | $50.09 | $75.28 | +27% | Bullish | |
| $41.89 | $62.02 | $99.53 | +58% | Bullish | |
| $44.40 | $69.44 | $117.14 | +77% | Bullish | |
| $56.62 | $93.06 | $163.61 | +137% | Bullish | |
| $72.08 | $124.14 | $226.12 | +216% | Bullish | |
| $80.79 | $145.50 | $273.46 | +270% | Bullish | |
| $83.87 | $157.70 | $304.83 | +301% | Bullish | |
| $82.01 | $160.83 | $318.93 | +309% | Bullish | |
| $90.49 | $184.95 | $375.49 | +370% | Bullish | |
| $160.78 | $357.30 | $798.82 | +809% | Bullish | |
| $345.83 | $768.52 | $1,767.59 | +18.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.70 | $39.32 | $49.37 | +0.00% |
| August 2026 | $34.29 | $41.62 | $52.66 | +5.84% |
| September 2026 | $32.94 | $40.58 | $52.46 | -2.50% |
| October 2026 | $31.89 | $39.78 | $52.37 | -1.96% |
| November 2026 | $32.77 | $41.33 | $55.23 | +3.90% |
| December 2026 | $33.17 | $42.26 | $57.23 | +2.23% |
Click any year to see its month-by-month MPLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MPLT is projected to trade between $15.70 and $57.23, averaging $39.32 — a potential gain of 0% from today's $39.32. Price action looks broadly range-bound.
MapLight Therapeutics, Inc.'s 2027 outlook centres on $50.09, within a $36.06 to $75.28 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MPLT could reach as high as $99.53, with a base case around $62.02 and support toward $41.89 — roughly +58% from $39.32. Momentum favours further upside here.
Expect MPLT to range from $44.40 to $117.14 through 2029. The $69.44 average target implies a +77% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MPLT price prediction for 2030 points to an average of $93.06 (low $56.62, high $163.61) — a potential gain of +137% on today's $39.32. Momentum favours further upside here.
In 2031, MPLT is projected to trade between $72.08 and $226.12, averaging $124.14 — a potential gain of +216% from today's $39.32. That is up +33% on the projected 2030 average. Buyers look set to stay in control over this stretch.
MapLight Therapeutics, Inc.'s 2032 outlook centres on $145.50, within a $80.79 to $273.46 range. That is up +17% on the projected 2031 average. That marks a +270% change versus current levels. Momentum favours further upside here.
By 2033, MPLT could reach as high as $304.83, with a base case around $157.70 and support toward $83.87 — roughly +301% from $39.32. Buyers look set to stay in control over this stretch.
Expect MPLT to range from $82.01 to $318.93 through 2034. The $160.83 average target implies a +309% move from current prices. That is up +2% on the projected 2033 average. Momentum favours further upside here.
The MPLT price prediction for 2035 points to an average of $184.95 (low $90.49, high $375.49) — a potential gain of +370% on today's $39.32. Buyers look set to stay in control over this stretch.
In 2040, MPLT is projected to trade between $160.78 and $798.82, averaging $357.30 — a potential gain of +809% from today's $39.32. That is up +93% on the projected 2035 average. Momentum favours further upside here.
MapLight Therapeutics, Inc.'s 2050 outlook centres on $768.52, within a $345.83 to $1,767.59 range. That is up +115% on the projected 2040 average. That marks a +18.5x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MPLT today (≈ 25.43235 MPLT) could be worth
$19,545.23
+$18,545.23 (+1855%) by 2050 · US Dollar
Based on the average projected MPLT price of $768.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MPLTwould be worth at today's price.
$1,000 invested in MPLT on Oct 27, 2025 (≈ 54.525627 MPLT) would be worth
$2,143.95
+$1,143.95 (+114.4%) today · 2.14× · US Dollar
Based on a MPLT entry price of $18.34 vs. today's $39.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.09 | $1,060.12 | +6.0% |
| 1 month ago | $27.8 | $1,414.39 | +41.4% |
| 3 months ago | $26.73 | $1,471.01 | +47.1% |
| 6 months ago | $19.07 | $2,061.88 | +106.2% |
| All time ago | $18.34 | $2,143.95 | +114.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MPLT forecast.
Our base-case forecast reaches $79.00 around 2030.
Implied market cap at $79.00: $3.37B
The multi-year forecast paints a bullish trajectory from 2027 onward, with the 2027 average price at $50.51 and higher momentum through 2030 at $94.56 average (ROI 137.6%), 2040 at $360.48 average (ROI 805.7%), and 2050 at $776.99 average (ROI 1852.3%). These projections imply a strong upward trend across the 2020s into the 2040s and beyond, albeit with significant uncertainty and real-world risks that could alter outcomes. The sentiment remains BULLISH for the longer horizon, reflecting expectations of continued growth and market expansion for MPLT’s CNS-focused portfolio.
Tap a question to reveal the answer.
2030 forecast: min $56.84, avg $94.56, max $167.81; ROI 137.6%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and positive ROIs (e.g., 2027 avg $50.51, ROI 26.9%; 2030 avg $94.56, ROI 137.6%; 2040 avg $360.48, ROI 805.7%; 2050 avg $776.99, ROI 1852.3%). These are estimates, not guarantees.
Yes. The 2035 forecast shows min $88.96, avg $185.78, max $381.62 with ROI 366.8 and a bullish sentiment, indicating potential to exceed $100.
2026 forecast: min $15.70, avg $39.80, max $58.08; ROI 0; sentiment NEUTRAL.
2040 forecast: min $162.22, avg $360.48, max $816.53; ROI 805.7; sentiment BULLISH.
MapLight Therapeutics, Inc. Community Discussion
0Share your MapLight Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.